ArticleScientific reports2026
QT-prolonging antipsychotic combinations and associated risk in hospitalized patients with mental disorders in Sana'a, Yemen.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prolongation of the QT interval is associated with serious and potentially life-threateningcardiac complications, requiring careful clinical attention. Psychiatric inpatients frequently receive multiple antipsychotic medications, some of which are known to affect cardiac repolarization. This study aimed to describe the patterns of QT-prolonging antipsychotic drug combinations and their associated drug-drug interaction (DDI) risk among hospitalized male participants in Sana'a, Yemen. A retrospective cross-sectional study was conducted using medical records of inpatients admitted to two psychiatric hospitals between November 2023 and June 2024. A total of 191 male participants aged 17-65 years who received antipsychotic polypharmacy for at least one week were included. Electrocardiogram (ECG) monitoring at admission was available for 47 participants. Prescribed medications were screened for QT-prolonging potential and interaction severity using the Arizona Center for Education and Research on Therapeutics (AZCERT) database. Overall, 395 QT-prolonging antipsychotic prescriptions were identified. Among participants receiving antipsychotic combinations, 36% were prescribed at least one strong-to-moderate QT-prolonging combination. Of the 47 participants who underwent ECG monitoring, 39.3% received drugs classified by AZCERT as having a known risk of torsades de pointes (TdP). Borderline QTc intervals were observed in 10.6% of participants, while 6.4% exhibited prolonged QTc intervals. These findings highlight the presence of QTc abnormalities within a pre-selected subgroup of psychiatric inpatients already receiving QT-prolonging antipsychotic polypharmacy. While no cases of TdP were observed, the results underscore the importance of enhanced clinical vigilance, routine ECG monitoring, and careful selection of antipsychotic combinations. Future studies including comparator groups are needed to quantify the incremental risk of QTc prolongation and TdP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.